15/05/1402
Anti-angiogenic peptides application in cancer therapy; a review
Cancer is a disease advanced via surplus angiogenesis. The development
of new anti-angiogenic therapeutic agents with more efficacy and fewer
side effects is still quite necessary. Conventional therapies saving the
life of many cancer patients but due to drug resistance and lack of
specificity utilizing these methods is faced with limits. Recently, new
therapeutic agents have been developed and used to treat cancers such as
scaffold proteins, monoclonal antibodies, tyrosine kinase inhibitors,
and peptides. In antiangiogenic drug development, anti-angiogenic
peptides design is a significant aim. Peptides have developed as
substantial therapeutics that are being carefully investigated in
angiogenesis-dependent diseases because of their high penetrating rate
into the cancer cells, high specificity, and low toxicity. In this
review, we focus on anti-angiogenic peptides in the field of cancer
therapy that are designed, screened, or derived from nanobodies,
mimotopes, phage displays, and natural resources.